MB
NUVB icon

MPM BioImpact’s Nuvation Bio NUVB Stock Holding History

MPM BioImpact’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,622,590
Closed -$9.01M – 46
2025
Q2 		$9.01M Sell
4,622,590
-29,653
-0.6% -$61.8K 1.56% 31
2025
Q1 		$8.19M Buy
4,652,243
+488,065
+12% +$1.11M 1.41% 32
2024
Q4 		$11.1M Buy
+4,164,178
New +$10.7M 1.57% 30

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

MPM BioImpact's NUVB Position: Q3 2025 in Review

MPM BioImpact sold out of Nuvation Bio (NUVB) in Q3 2025, closing a stake of 4,622,590 shares — an estimated $9.01M sold.

MPM BioImpact first reported a position in NUVB in Q4 2024 and held it in 3 quarters. The position peaked at $11.1M in Q4 2024. 203 funds tracked by Wall St. Rank hold NUVB as of Q3 2025.

  • MPM BioImpact reported no remaining Nuvation Bio position as of Q3 2025 after selling out during the quarter.
  • MPM BioImpact sold 4,622,590 Nuvation Bio shares in Q3 2025, an estimated $9.01M.
  • MPM BioImpact first reported a position in Nuvation Bio in Q4 2024 and held it in 3 quarters.
  • MPM BioImpact's Nuvation Bio position peaked at $11.1M in Q4 2024.
  • 203 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2025.

Based on MPM BioImpact's 13F filing for Q3 2025, filed 14 Nov 2025.